The economic burden is considerable: annual direct healthcare costs attributable to MASLD in the United States and Europe are estimated in the tens of billions of dollars, driven by hospitalizations, liver-related procedures, and management of comorbid conditions [6]
The truth is more nuanced: GLP-1 medications can be part of a long-term care plan, but ongoing success depends on understanding how appetite, metabolism, and daily habits work together
Changes to the shortage list - specifically, the removal of a drug from the list - trigger significant legal and business consequences for the compounding industry
Most patients then move to 1.0 mg weekly as their maintenance dose, though some progress to 2.4 mg depending on their response and tolerability
Unlike the array of new injectable GLP-1 drugs, there is only one oral GLP-1 medicine that is currently on the market: Novo Nordisks Rybelsus
No need for separate bacteriostatic water and reconstitution syringes